Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Sponsors › Genomics: Clinical Implementation › ArcherDx, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers

ArcherDx, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers

Apr 21, 2020
|
staff reporter

NEW YORK ─ ArcherDx and Premier said today that they have signed a two-part agreement that kicks off a multiyear program to deliver personalized genomic testing to patients.

The goal of the partnership is to help mitigate underutilization of targeted therapies in late-stage cancer patients, ArcherDx said.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In Molecular Diagnostics

  1. Guardant Health to Develop Liquid Biopsy Companion Diagnostic for Janssen NSCLC Therapy

  2. Thermo Fisher Scientific, Chugai Pharmaceutical Sign Companion Diagnostic Agreement for NSCLC

  3. Payor Policy Study Reveals Progress, Challenges in Liquid Biopsy Reimbursement

  4. GNS Healthcare, MMRF Bring Patient Simulations to Multiple Myeloma Precision Treatment, Trial Design

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.